U.S. RESEARCH ROUNDUP-Avidity Biosciences, Broadcom, Cara Therapeutics June 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Avidity Biosciences, Broadcom and Cara Therapeutics, on Thursday. HIGHLIGHTS * Avidity Biosciences Inc RNA.O : Leerink Partners raises target price to $56 from $38 * Broadcom Inc AVGO.O : TD Cowen raises target price to $1,750 from $1,500 * Cara Therapeutics Inc CARA.O : Canaccord Genuity cut

BRIEF-Iqvia Launches “One Home” Clinical Trial Technology Platform – Solves Challenges And Reduces Overload At Sites June 12 (Reuters) - IQVIA Holdings Inc IQV.N : IQVIA LAUNCHES “ONE HOME” CLINICAL TRIAL TECHNOLOGY PLATFORM – SOLVES CHALLENGES AND REDUCES OVERLOAD AT SITES Source text for Eikon: ID:nBw7w4l7Ta Further company coverage:

BUZZ-UK's Hikma gains as Citi raises target price ** Shares of British drugmaker Hikma Pharmaceuticals HIK.L up 3% at 1,989p ** Stock is top pct gainer on FTSE 100 index .FTSE ** Brokerage Citigroup raises target price to 2845p from 2770p ** Research firm IQVIA's data on HIK highly encouraging; we go to the top-end of forecast range - Citi ** Hikma

IQVIA trims full-year revenue forecast on stronger dollar May 2 (Reuters) - Contract research firm IQVIA Holdings IQV.N lowered its annual revenue forecast on Thursday due to a stronger dollar and reported a quarter-over-quarter fall in a closely-watched metric, sending shares down nearly 4%. The company expects 2024 revenue of $15.33 billion to $15.58 billion, versus its previous forecast of between $15.4 billion and $15.65 billion, as a strengthening dollar hit sales in its large international

IQVIA Holdings Inc reports results for the quarter ended in March - Earnings Summary IQVIA Holdings Inc IQV.N reported quarterly adjusted earnings of $2.54​​ per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $2.45. The mean expectation of twenty analysts for the quarter was for earnings of $2.48 per share.